Xu Lang, Li Yuhong, Yan Dan, He Jun, Liu Dan
Department of Pathology, Medical College, Wuhan University of Science and Technology, Wuhan 430065, P.R. China.
Oncol Lett. 2014 Nov;8(5):2345-2351. doi: 10.3892/ol.2014.2504. Epub 2014 Sep 5.
The aberrant expression of microRNA-183 (miRNA/miR-183) has been found to be involved in numerous tumor types. However, the role of miR-183 in gastric cancer pathology is unclear and requires investigation. In the present study, the miR-183 expression levels of gastric cancer cell lines and tissues obtained from gastric cancer patients were measured by reverse transcription quantitative polymerase chain reaction analysis. The effect of miR-183 on gastric cancer cell proliferation and invasion was evaluated using MTT, colony formation and Transwell assays. The target of miR-183 was identified and confirmed using a luciferase activity assay. The results revealed that miR-183 was significantly downregulated in gastric cancer cells compared with GES-1 normal gastric epithelial cells. In addition, miR-183 was reduced in gastric cancer tissues compared with adjacent normal tissues. The ectopic expression of miR-183 significantly inhibited gastric cancer cell proliferation, colony formation and invasion. Bmi-1 was also confirmed as a downstream target of miR-183 in the gastric cancer cells by western blot analysis and luciferase activity assays. In conclusion, miR-183 is downregulated in gastric cancer cells and tissues, and inhibits gastric cancer cell proliferation and invasion by targeting Bmi-1. Therefore, targeting miR-183 may be a potential therapeutic strategy in gastric cancer patients.
已发现微小RNA-183(miRNA/miR-183)的异常表达与多种肿瘤类型有关。然而,miR-183在胃癌病理中的作用尚不清楚,需要进行研究。在本研究中,通过逆转录定量聚合酶链反应分析测定了胃癌患者的胃癌细胞系和组织中miR-183的表达水平。使用MTT、集落形成和Transwell实验评估了miR-183对胃癌细胞增殖和侵袭的影响。使用荧光素酶活性测定法鉴定并确认了miR-183的靶标。结果显示,与GES-1正常胃上皮细胞相比,miR-183在胃癌细胞中显著下调。此外,与相邻正常组织相比,胃癌组织中miR-183降低。miR-183的异位表达显著抑制了胃癌细胞的增殖、集落形成和侵袭。通过蛋白质免疫印迹分析和荧光素酶活性测定,Bmi-1也被确认为胃癌细胞中miR-183的下游靶标。总之,miR-183在胃癌细胞和组织中表达下调,并通过靶向Bmi-1抑制胃癌细胞的增殖和侵袭。因此,靶向miR-183可能是胃癌患者的一种潜在治疗策略。